

Human Prion Disease Research and Resource Centre

Terms of Reference

- 1. Maintain an archive of blood and tissue samples from individuals with human prion disease, persons with an increased risk of prion disease and relevant healthy and disease controls.
- 2. Maintain an archive of animal samples that may represent animal models for all types of and stages of human prion disease.
- 3. Develop protocols whereby wet ante mortem biomarker tests for human prion disease may be evaluated, and to propose processes for the evaluation of such tests.
- 4. Perform evaluations of ante mortem tests referred to the Centre by the Oversight Committee.
- 5. Manage the distribution of samples from the archive
- 6. Ensure that all activities undertaken are compliant with ethical and legal requirements.
- 7. Ensure coordination and liaison between the Research and Resource Centre and the Oversight Committee with other advisory committees with overlapping interests.
- 8. Carry out relevant research to support the work of the Research and Resource Centre.
- 9. Provide secretariat to Oversight Committee.
- 10. Pursue international collaboration to facilitate these activities.



Human Prion Disease Resource Oversight Committee

Terms of Reference

- 1. Provide developers of wet ante mortem biomarker tests for human prion disease with an opportunity for independent evaluation of the tests suitability for purpose.
- 2. Agree the processes proposed by the Research and Resource Centre for the evaluation of ante mortem tests for human prion disease.
- 3. Refer wet ante mortem biomarker tests for human prion disease to CJD Research and Resource Centre for evaluation.
- 4. Review, and provide advice on, the application by the Centre of the evaluation processes.
- 5. Review the outputs of the evaluation processes, and report these to the test developer and appropriate advisory committees. Encourage publication of evaluation outcomes.
- 6. Review and agree proposals for the distribution of samples.